352 related articles for article (PubMed ID: 11145220)
1. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers.
Liang E; Proudfoot J; Yazdanian M
Pharm Res; 2000 Oct; 17(10):1168-74. PubMed ID: 11145220
[TBL] [Abstract][Full Text] [Related]
2. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
3. MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting.
Dahan A; Amidon GL
Int J Pharm; 2010 Feb; 386(1-2):216-20. PubMed ID: 19944137
[TBL] [Abstract][Full Text] [Related]
4. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
6. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter.
Horie K; Tang F; Borchardt RT
Pharm Res; 2003 Feb; 20(2):161-8. PubMed ID: 12636153
[TBL] [Abstract][Full Text] [Related]
8. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
9. An in vitro and in silico study on the flavonoid-mediated modulation of the transport of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) through Caco-2 monolayers.
Schutte ME; Freidig AP; van de Sandt JJ; Alink GM; Rietjens IM; Groten JP
Toxicol Appl Pharmacol; 2006 Dec; 217(2):204-15. PubMed ID: 16997339
[TBL] [Abstract][Full Text] [Related]
10. Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
[TBL] [Abstract][Full Text] [Related]
11. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.
Batrakova EV; Li S; Miller DW; Kabanov AV
Pharm Res; 1999 Sep; 16(9):1366-72. PubMed ID: 10496651
[TBL] [Abstract][Full Text] [Related]
12. Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2.
Watanabe K; Sawano T; Terada K; Endo T; Sakata M; Sato J
Biol Pharm Bull; 2002 Jul; 25(7):885-90. PubMed ID: 12132663
[TBL] [Abstract][Full Text] [Related]
13. Transport characteristics of fexofenadine in the Caco-2 cell model.
Petri N; Tannergren C; Rungstad D; Lennernäs H
Pharm Res; 2004 Aug; 21(8):1398-404. PubMed ID: 15359574
[TBL] [Abstract][Full Text] [Related]
14. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.
Makhey VD; Guo A; Norris DA; Hu P; Yan J; Sinko PJ
Pharm Res; 1998 Aug; 15(8):1160-7. PubMed ID: 9706044
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
[TBL] [Abstract][Full Text] [Related]
17. Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers.
Annaert P; Van Gelder J; Naesens L; De Clercq E; Van den Mooter G; Kinget R; Augustijns P
Pharm Res; 1998 Aug; 15(8):1168-73. PubMed ID: 9706045
[TBL] [Abstract][Full Text] [Related]
18. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
19. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
20. Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone.
Wu SJ; Robinson JR
Pharm Res; 1999 Aug; 16(8):1266-72. PubMed ID: 10468030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]